Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label maralixibat study in infants with Alagille syndrome or progressive familial intrahepatic cholestasis
2020-004628-40Phase 2Completed
- Sponsor
- Mirum Pharmaceuticals, Inc.
- Start
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of maralixibat in Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC), sponsored by Mirum Pharmaceuticals, Inc. Primary endpoint: Safety. Started Dec 2020; status: completed.
02
Drugs
maralixibat
03
Conditions
Alagille syndrome (ALGS)progressive familial intrahepatic cholestasis (PFIC)
Beyond the preview
Go deeper on 2020-004628-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004628-40.